News about "Dr Chris Chen"

WuXi Biologics Receives Brazil GMP Certification for Cancer Therapy Manufacturing

WuXi Biologics Receives Brazil GMP Certification for Cancer Therapy Manufacturing

WuXi Biologics has received Brazil ANVISA GMP certification with zero inspection findings, enabling global commercial manufacturing of its innovative cancer immunotherapy.

Dr. Chris Chen | 02/07/2026 | By News Bureau

WuXi Biologics Secures 4th EMA GMP Certification for Suzhou Facility

WuXi Biologics Secures 4th EMA GMP Certification for Suzhou Facility

WuXi Biologics’ Suzhou Biosafety Testing Center has received its 4th EMA GMP certification, supporting European Union (EU) Marketing Authorisation (MA) applications for 19 biologics from 13 stakeholders.

Dr. Chris Chen | 18/06/2026 | By News Bureau

WuXi Biologics Completes Topping-Out of Singapore Drug Product Facility

WuXi Biologics Completes Topping-Out of Singapore Drug Product Facility

WuXi Biologics has completed the modular topping-out of its Singapore CRDMO hub drug product facility, a key manufacturing site designed to meet stringent standards. Once operational, the facility is expected to produce approximately 100 million pre-filled syringes and vials annually.

Dr. Chris Chen | 06/06/2026 | By News Bureau 114

WuXi Biologics Signs Global Licensing Deal with Vertex for Trispecific T Cell Engager in Autoimmune Diseases

WuXi Biologics Signs Global Licensing Deal with Vertex for Trispecific T Cell Engager in Autoimmune Diseases

WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.

Dr. Chris Chen | 03/02/2026 | By News Bureau 220

WuXi Biologics, Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases

WuXi Biologics, Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases

WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development of SND006, a novel bispecific antibody targeting inflammatory bowel disease and autoimmune disorders.

Dr. Chris Chen | 29/01/2026 | By News Bureau 208

WuXi Biologics' Wuxi Facilities Receive MHRA GMP Approval for Ophthalmic Biologic Manufacturing

WuXi Biologics' Wuxi Facilities Receive MHRA GMP Approval for Ophthalmic Biologic Manufacturing

The UK regulator has certified WuXi Biologics’ DP5 and DPPC sites in Wuxi for commercial production, reinforcing the company’s global GMP-compliant manufacturing capabilities.

Dr. Chris Chen | 13/01/2026 | By News Bureau 243

WuXi Biologics Extends CRDMO Footprint to Qatar

WuXi Biologics Extends CRDMO Footprint to Qatar

WuXi Biologics has signed an MoU with the Qatar Free Zones Authority (QFZ) to expand its global footprint into the Middle East. The partnership sets the stage for the company’s first integrated CRDMO centre in the region, strengthening its worldwide research, development, and manufacturing capabilities.

Dr Chris Chen | 02/12/2025 | By Dineshwori 370


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members